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MULTILEVEL FACTORS IN CANCER SCREENING 
Joshua B. Demb 
ABSTRACT 
 Cancer is the second leading cause of death in the United States, with cancer of the 
breast and cancer of the lung and bronchus together accounting for approximately 29% of all 
cancer cases and 32% of all cancer deaths.  Cancer screening tests are a means to reduce 
mortality of these two cancer types.  While the current guidelines aim to maximize the potential 
benefits from screening while minimizing harms, there is still significant effort needed to achieve 
optimal breast and lung cancer screening uptake.  This dissertation builds upon recent research 
leveraging multilevel frameworks to examine factors affecting cancer screening use and their 
importance in clinical practice and in screening guidelines. 
 The first chapter comprehensively examines the current evidence regarding how various 
life expectancy factors are associated with screening mammography uptake among women 
ages 65 and older.  The primary objective was to understand the important role life expectancy 
could play in patient-provider communication regarding whether to continue screening at an 
advanced age.  The second chapter focuses on the variation in performance of lung cancer 
screening scans, which use low-dose computed tomography.  This project sought to identify the 
potential institutional-level predictors that could lead to radiation doses outside the current 
guidelines for these scans, potentially impacting the expected margin of benefit from screening.  
The third and final chapter is a multilevel assessment of the effect of employment status on 
screening mammography utilization during the Great Recession, to better understand how 
societal changes can influence individual-level cancer screening behaviors.   
 Together these projects highlight the interdependence of factors at multiple levels in the 
cancer screening environment.  Examination of these multilevel factors can improve integration 
of new interventions to optimize cancer screening uptake and ensure that early detection 
practices are successful, thus improving treatment outcomes and maximizing survival.  
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1. INTRODUCTION 
 Cancer is the second leading cause of death in the United States.1 In 2018, it is 
estimated that there will be over 1.7 million new cases of cancer diagnosed in the United States, 
and over half a million people will die from cancer.2,3 The two leading anatomic sites of cancer 
incidence and death are cancers of the lung and bronchus and cancers of the breast, which 
together account for approximately 29% of all new cancer cases and 32% of all cancer deaths 
in the United States.3 Further, it is estimated that the yearly national expenditures for cancer 
care in the United States will exceed $170 billion over the next two years.4 The ongoing burden 
of these cancers and their relative contribution to mortality in the United States highlights the 
need to prioritize early detection of cancer to improve the likelihood of successful cancer 
treatment and lower risk of mortality.   
 Cancer screening is an important secondary prevention method with an overarching goal 
to reduce the burden of cancer morbidity and mortality by detecting a tumor before the onset of 
symptoms.5 To achieve this goal, the ideal cancer screening regimen must maximize potential 
benefits—such as earlier detection of cancer and longer survival among eventual cancer 
cases—against possible harms, such as detection of indolent or slow-growing cancers with low 
risk of becoming malignant (overdiagnosis) or the risk of false-positive screening results, both of 
which lead to unnecessary and potentially invasive diagnostic workup.5,6 As more evidence is 
found regarding the efficacy of different types of cancer screening, the recommendations and 
guidelines evolve to maximize the margin of benefit.7 
Screening mammography has been an endorsed breast cancer screening tool for more 
than 50 years, with several recent quality improvements occurring within the last 20 years, 
including the development of the Mammography Quality Standards Act in 1992.8–11 Screening 
for lung cancer—a low-dose computed tomography (LDCT) scan—on the other hand, was 
found to have a potential benefit within the last 15 years.12–14 Table 1.1 shows the criteria for 
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which the U.S. Preventive Services Task Force (USPSTF) currently supports both of these 
screening tests, which influences whether screenings are included as essential health benefits 
as part of healthcare coverage.15  In addition to the USPSTF guidelines, the US Department of 
Health and Human Services has sought to improve uptake of cancer screening as part of the 
Healthy People 2020 initiative, specifically targeting a 10% improvement in breast cancer 
screening uptake among eligible women.16  Furthermore, recent findings indicate that 
implementing current lung cancer screening guidelines in community health facilities is very 
challenging, and current guidelines are not being properly implemented.17–19 
Table 1.1: USPSTF screening guidelines for breast and lung cancer screening 
Screening Modality Mammography20 
(Breast Cancer) 
Low-dose CT21 
(Lung Cancer) 
Screening Frequency Biennial Annual 
Age of Initiation Age 50 Age 55 
Age of Cessation Age 74 Age 80 
Other Eligibility Factors None 30 pack-year smoking history 
Former Smokers: Quit ≤15 years 
prior to screening 
Note: These guidelines have A or B rating based on most recent USPSTF recommendations 
Despite these efforts, there is still more work to be done to achieve optimal breast and 
lung cancer screening implementation and uptake.  Achieving optimal cancer screening uptake 
requires that the guidelines adapt to current trends in cancer incidence and mortality, that a 
clear margin of benefit is maintained, and any harms are minimized.  At the same time, 
successful implementation of cancer screening in practice requires buy-in from providers and 
institutions and an understanding of the population needing to be screened.  Understanding 
these factors influences the development of policies that affect access to cancer screening 
services.  Accomplishing all of this requires a holistic assessment and more complex 
conceptualization of the system in which cancer screening tests exist.  
1.1 THE CANCER SCREENING SYSTEM 
In recent years, various researchers have developed different conceptualizations of the 
system in which cancer care exists.  One model, known as the Cancer Care Continuum, aimed 
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to identify different areas across the full spectrum of the natural history of cancer where health 
care quality could be improved in response to the Institute of Medicine report, Ensuring Quality 
Cancer Care.22,23 Even with this longitudinal approach to cancer care, a more complex system 
exists with multiple levels of influence that could affect provider delivery and patient utilization of 
cancer care services.22,24,25 Zapka et al. used this knowledge to develop a Quality in the 
Continuum of Cancer Care framework to evaluate the quality of secondary prevention in breast 
cancer and cervical cancer, highlighting the factors contributing to failures in care processes, as 
well as the potential strategies that could reduce failures.22 
In practice, a common approach for improving quality of care has been to focus on one 
of the individual steps within the cancer care continuum.  The problem, however, as Taplin et al. 
have argued, is that a lack of coordination or lack of patient-centered approach across the 
continuum leads to poor implementation of these improvments.26 Instead, they argue that care 
should be considered as “a process in a dynamic system”, leveraging the theory of complex 
adaptive systems to think about the entire system.26–29 This theory notes that individuals and 
layers within a system are constantly adapting to their surroundings.26   
McLeroy et al. explain a multilevel, interactive approach to epidemiology that focuses 
efforts on modifying organizational behavior and helps develop and advocate for policies that 
support public health behaviors.30,31  The model focuses on five levels of factors.  Intrapersonal 
factors emphasize characteristics of the individual, such as knowledge and behavior.  
Interpersonal processes and primary groups focus on the individual’s social network and 
support systems.  Institutional factors include social institutions with organizational 
characteristics.  Community factors focus on the relationships among organizations and 
institutions.  Finally, public policy encapsulates the local, state and national laws that govern the 
preceding levels of influence.30  Warnecke et al. developed a similar conceptual model, 
influenced by the efforts of Taylor et al.32, Berkman et al.33, and Glass and McAtee34 to model 
socio-ecological factors involved in population health.35  While this model is a more general 
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framework to understand population health, it clarifies the interplay of factors that can lead to 
disparate health outcomes, particularly within the cancer screening environment. 
Rimer and Glanz also apply an ecological framework to cancer screening epidemiology, 
highlighting two key themes: 1) behavior both affects and is affected by multiple levels of 
influence, and 2) individual behavior both shapes and is shaped by the social environment 
(reciprocal causation).31,36  Rimer and Glanz apply this framework to a case study of a woman 
deciding whether or not get a mammogram.31   
“A woman may weigh the pros and cons of getting a mammogram and hesitate to 
screen because of concerns about detecting cancer.  At the interpersonal level, this 
decision may never come up between her and her primary care provider, due to either 
minimization by the woman, or neglect to discuss on the part of the provider.  At the 
organizational level, the woman might change her mind and decide to get a 
mammogram, only to find out that scheduling an appointment is more difficult than she 
anticipated.  Further, the woman might realize that her health insurance does not fully 
cover the costs of a mammogram (institutional level).  The ultimate result to not screen is 
thus shaped by a host of factors at multiple levels.”31  
 
The outcome of this case study is particularly concerning in low income women and 
African American women, who are up to three times more likely to present with advanced stage 
cancer compared with other groups.37,38 Further, it stresses the importance about understanding 
the intersection of population risk and individual risk as it relates to cancer screening. 
To better understand how to improve current cancer screening practices, it is clear that 
research must adopt a complex systems approach.  Adapting conceptual frameworks from 
Zapka et al., Taplin et al., McLeroy et al., Rimer and Glanz and Warnecke et al., Figure 1.1 
emphasizes the cancer screening environment as whole, illustrating the multilevel factors and 
their interdependencies, and their impact on cancer screening utilization and the quality of 
cancer screening services.  Within this system, there are four major levels of factors: 1) 
structural factors, encompassing population-level effects; 2) system factors, focusing on aspects 
of healthcare such as insurance and access; 3) institutional factors, which include aspects of 
medical care within specific health institutions and provider-level effects; and 4) individual 
factors, focused on the patient and their interactions with the health care system.   
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Figure 1.1: Socio-ecological Framework of Multilevel Factors Involved in Cancer 
Screening. 
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 Chapter 1 is a systematic review and meta-analysis of the current literature of US-based 
studies examining the effect of life expectancy factors—comorbidity, functional status and 
prognostic factors—on screening mammography utilization in older women (women ages ≥65).  
This chapter focuses on the patient-provider interaction and contextualizing how life expectancy 
factors affect screening uptake, and how these factors should be considered when older women 
consider undergoing screening mammography.   Chapter 2 examines institutional and system 
factors in current computed tomography practices in lung cancer screening across several US 
institutions. It uses US data from an international radiation dose registry to understand the 
factors that influence variation in radiation doses for the scans, which can affect the potential 
margin of benefit conferred from undergoing screening.  Finally, Chapter 3 addresses the 
interaction of structural and societal factors by leveraging data from the Health and Retirement 
Study to evaluate the effect of employment status on screening mammography utilization 
before, during and after the Great Recession (2007-2009).  In this final chapter, the goal was to 
understand whether temporal trends existed in this association, notably whether being less than 
full-time employed during the Great Recession led to lower screening mammography utilization. 
On their own, each chapter evaluates an important question that exists within different 
ecological levels of the cancer screening environment.  Examined together, these projects 
contextualize the individual-, institutional- and structural-level factors that influence cancer 
screening in practice and in policy, and further exemplify the importance of understanding 
cancer screening from a systematic perspective.   
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2. CHAPTER 1: Screening mammography use in older women according to health 
status: a systematic review and meta-analysis 
Joshua Demb MPH, Tomi Akinyemiju PhD, Isabel Allen PhD, Tracy Onega PhD, Robert A. Hiatt 
MD PhD, Dejana Braithwaite PhD 
 
 
 
Figure 2.1: Conceptual Framework for Multilevel Factors Involved in Cancer Screening, 
Multilevel Factors for Chapter 1 Highlighted 
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2.1 ABSTRACT 
Background: The extent to which screening mammography (SM) recommendations in older 
women incorporate life expectancy factors is not well established.   
Objective: Evaluate evidence on SM utilization in older women by life expectancy factors.  
Data Sources: MEDLINE, EMBASE and Web of Science from January 1991 to March 2016. 
Study Selection: We included studies examining SM utilization in women ages ≥65 years that 
measured life expectancy using comorbidity, functional limitations or health or prognostic status.   
Data Extraction and Synthesis: Odds ratios and 95% confidence intervals (CIs) were 
extracted and grouped by life expectancy category.  Findings were aggregated into pooled odds 
ratios and 95% CIs and meta-analyzed by life expectancy category.   
Main Outcomes and Measures: The primary outcome was SM utilization within the last five 
years.  Life expectancy factors included number of comorbidities, Charlson Comorbidity Index 
(CCI), activities of daily living, instrumental activities of daily living, self-reported health status 
and 5-year prognostic indices.  
Results: Of 2606 potential titles, we identified 25 meeting the inclusion criteria (Comorbidity: 8 
studies; Functional Status: 11 studies; Health/Prognostic Status: 13 studies).  Women with 
higher CCI scores had decreased SM utilization (Pooled OR: 0.75 95% CI: 0.67-0.85) but 
increased absolute number of comorbidities were weakly associated with increased SM 
utilization (Pooled OR: 1.17 95% CI: 1.00-1.36).  Women with more functional limitations had 
lower SM use odds than women with no limitations (Pooled OR: 0.72 95% CI: 0.62-0.83). 
Screening utilization odds were lower among women with poor versus excellent health (Pooled 
OR: 0.85 95% CI: 0.74-0.96). 
Conclusion: Greater CCI score, functional limitations and lower perceived health were 
associated with decreased SM use, whereas higher absolute number of comorbidities was 
associated with increased SM use. SM guidelines should consider these factors to improve 
assessments of potential benefits and harms in older women.  
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2.2 INTRODUCTION 
More than 50% of new invasive breast cancer cases diagnosed each year in the United 
States (U.S.) occur among older women—women ages 65 years and older.39 The increasing life 
expectancy of women in the US and attendant rise in the absolute number of breast cancer 
cases in older women will likely lead to an increasing absolute number of mammograms 
performed in the ≥65 age group.40  In 2010, the United States Centers for Disease Control and 
Prevention estimated that older women reported the highest prevalence of mammography use 
within the past two years.41  However, the U.S. Preventive Services Task Force currently does 
not recommend screening mammography in women ages 75 and older due to insufficient 
evidence.20  Although older women have a higher risk of breast cancer and lower risk of false-
positive mammography results than younger women, their shorter life expectancy decreases the 
potential benefits of screening.20,42,43  
A recent review concluded that screening for breast cancer is most appropriate for 
women with a life expectancy of at least 10 years.44 Because the full benefit of screening is only 
realized with reduction in mortality, numerous studies have accounted for life expectancy factors 
to better identify the margin of benefit a woman might expect from undergoing screening.41,44–47 
To date, comorbidity burden, functional status, and self-reported heath are the strongest 
predictors of life expectancy.48–51  However, the current guidelines for screening mammography 
do not account for life expectancy factors other than chronological age.20,52 
In light of the current demographic, epidemiologic, and policy environment, it is important 
to understand the extent to which the current practice of screening mammography is targeted to 
healthy older women and avoided in older women with limited life expectancy. In this study, we 
report the results of a systematic review and meta-analysis of the literature of studies assessing 
mammography screening utilization rates of older women in relation to age, functional 
limitations, and health status, including but not limited to comorbidity. The main objective of this 
study is to outline the current practices that exist for screening mammography utilization in older 
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women and the association between screening and life expectancy factors in order to help 
guide future screening mammography guidelines.  
2.3 METHODS 
 This systematic review and meta-analysis has a published protocol,53 and is registered 
with PROSPERO with the registration number, CRD42016032661. A PRISMA checklist is 
included in Appendix Table S1.  The study is covered under an IRB with exempt status 
submitted and approved by the University of California, San Francisco IRB.   
Search strategy and selection criteria  
We performed a systematic search of the literature using MEDLINE (using PubMed 
interface), EMBASE, and Web of Science (January 1, 1991-March 1, 2016) to identify relevant 
studies. “Breast neoplasms” was combined with the permutations, variations, and abbreviations 
of the relevant Medical Subject Headings (MeSH) keywords and non-MeSH key terms for 
mammography, age, health status and comorbidity, including (e.g., cardiovascular diseases, 
comorbidity, cognition disorders, diabetes mellitus, functional limitation, health status, 
myocardial infarction, stroke, etc.). Complete search strategies are provided in the Appendix 
Sections 2.7.1 and 2.7.2.  
The broad criteria for this review allowed for the evaluation of multiple study designs 
published in English. The inclusion criteria were as follows: i) women aged 65 years and older in 
the United States, ii) assessment of women’s comorbidity (either as a specific condition or a 
summary score) and/or functional impairments and/or health status, and iii) an outcome 
measure that addresses recent screening mammography utilization. Additional studies were 
obtained through citations of review articles or contacting breast cancer screening experts 
regarding any unpublished articles that may be suitable for inclusion in the systematic review. 
Case reports were excluded.  Data were extracted from the full text article.  
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Most, if not all, of the target population is Medicare beneficiaries, with screening 
mammography covered based on policy changes implemented in 1991.54 At that time, Medicare 
Part B medical insurance, for which most women become eligible when they turn 65 years, 
covered the full cost of annual mammography for all women age 40 and over.20,40 To account for 
this Medicare policy change, we excluded studies evaluating screening utilization prior to 
1991.54 Women eligible for Medicare ages 65-74 are near the upper limit of the USPSTF 
primary screening mammography guidelines (age 74 years) and USPSTF guidelines note that 
data are currently inconclusive to provide screening recommendations for women ages 75 and 
older.55  
Quality assessment and data extraction 
To evaluate the quality of included studies, we used the Newcastle-Ottawa Scale (NOS) 
and Cochrane Collaboration Risk of Bias (CCRB) tool56,57 to evaluate observational studies and 
clinical trials, respectively. The NOS measures the methodological quality of observational 
studies, giving predefined criteria, some of which have to be further specified based on topic. 
We specified these criteria in a consensus meeting with the authors (Appendix Tables S2A 
and S2B) before assessing the studies.  
Studies were assessed for quality of selection (representativeness, selection of controls, 
ascertainment of exposure); comparability (adjustment for confounding); and outcome or 
exposure (assessment of outcome/exposure, length and adequacy of follow-up) independently 
by two authors (JD and TA).  Measures of age, socio-economic status (such as race, education, 
income), health insurance, and number of physician visits were identified as important 
confounders. Cohort and case-control studies could earn a maximum of 9 points, and cross-
sectional and randomized clinical trials could earn a maximum of 10 points.  Studies with scores 
of 6 to 8 points were considered to be of moderate-to-good study quality, and scores of 9 or 
higher were deemed excellent. All studies were summarized irrespective of quality score.  
A data extraction form was used to collect study characteristics, including type of study, 
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number of participants, length of follow-up, exposure(s), outcome(s), and quality assessment.  
Exposures logged in this form were life expectancy factors, including comorbidity scales or 
specific diseases considered, functional limitation scales used, and measures of health status. 
The primary outcome was screening mammography utilization, defined as screening 
mammography occurring within the last 1-5 years.  We extracted odds ratios and corresponding 
95% confidence intervals (CIs) from most studies, with some studies providing risk ratios or 
proportions of utilization.  Quantitative results were extracted from text and tables, choosing 
preferably those adjusted for important confounders.  Two authors (JD and TA) independently 
performed study quality assessment and data extraction.  Discrepancies were discussed and 
resolved by the review team.   
Qualitative Synthesis and Meta-Analysis 
 We conducted a qualitative synthesis to describe the findings of included studies, 
explore associations of interest and examine the quality of the studies and robustness of the 
systematic review. Study findings were separated into the four exposure categories: comorbidity 
(measured using an absolute count, Charlson Comorbidity Index (CCI) and individual disease 
conditions), functional limitations (activities of daily living, instrumental activities of daily living), 
health status and prognostic status. For each exposure, we aggregated study findings to 
perform meta-analyses assessing the overall magnitude of the association with recent 
screening mammography utilization. Pooled ORs and corresponding 95% CIs were reported.  
Given the variation in measurement of exposures, we stratified our findings to address study 
heterogeneity.  Heterogeneity was measured using I2 values and Cochran’s Q statistic.  Pooled 
results were analyzed using random effects models to control for heterogeneity.  
We also performed sensitivity analyses to examine potential publication bias including 
jackknife analyses58 and reported these findings in addition to the primary study findings and 
subgroup analyses.59 We also performed meta-regression to understand how study traits 
contributed to heterogeneity of pooled effect estimates.60,61  The meta-analysis results are 
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graphically displayed using forest plots.59 All analyses were performed using STATA 13 (Stata, 
College Station, TX, USA). 
2.4 RESULTS 
Study characteristics, including number of subjects, age range, years of data accrual, 
study design, assessment of outcome and assessment of exposure are summarized in Table 
2.1. We tabulated the full Newcastle Ottawa findings of individual studies for descriptive 
purposes (see Appendix Tables S2A and S2B). Full descriptive results by exposure type are 
found in Appendix Tables S3-S5. 
Literature search 
We identified 2,606 potentially relevant titles through PubMed, EMBASE, and Web of 
Science (see PRISMA flowchart in Figure 2.2). After excluding titles that: did not report (a) 
screening mammography utilization, (b) comorbidity, health status and/or functional status, (c) 
original research, did not include (d) populations from the United States, (e) screening 
mammography utilization prior to 1991 and (f) results for women <65 years old, we identified 
142 studies published between January 1,1991 and March 31, 2016.  After review of abstracts, 
we excluded 95 articles that did not meet the inclusion criteria.  After reviewing 47 full text 
articles,54, 62, 71–80, 63, 81–90, 64, 91–100, 65, 101–107,66–70 25 studies were included in the review, published 
between 1996 and 2016: there were 10 cohort studies66, 68,69, 76,77, 79, 93, 100,101,105 and 15 cross-
sectional studies.54, 64, 97–99, 102, 106, 70, 73,74, 81, 83, 88,89,96  No case-control studies were found, which 
is likely due to the highly common outcome of screening utilization. Characteristics of included 
studies are shown in Table 2.1.  Since 3 studies did not include odds ratios, only 22 of the 25 
studies were included in the meta-analysis.   
Quality Assessment 
 All of the studies used a combination of surveys, Medicare insurance claims data, and/or 
medical records to examine associations between the predictor(s)—comorbidity, functional 
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status or health status—and the outcome, mammography utilization.  Based on the quality 
assessment using the Newcastle-Ottawa Scale (no clinical trials were included),56 all studies 
were found to be of moderate to excellent quality, despite several studies using self-reported 
outcome assessment.  
Estimates of the effect of the comorbidity on utilization of screening mammography  
A full list of comorbidities measured in each study can be found in Appendix Tables 
S3A, S3B and S3C.  Eight studies measured the association of comorbidity with screening 
mammography utilization, with four studies using an unweighted number of comorbid conditions 
measure69, 74, 96,108 and four studies using the Charlson Comorbidity Index (CCI) (Figure 2.3).81, 
88, 101,106  The pooled result showed no significant association between comorbidity and 
screening mammography utilization (OR: 0.94 95% CI: 0.80-1.10).  However, when stratified by 
comorbidity measurement, increased comorbidity measured using CCI was associated with 
decreased screening mammography utilization (OR: 0.75 95% CI: 0.67-0.85), while increased 
absolute number of comorbidities was weakly associated with increased screening 
mammography utilization (OR: 1.17 95% CI: 1.00-1.36).  Meta-regression results indicated 
studies measuring comorbidity using CCI showed significantly lower screening mammography 
utilization (Pooled OR: 0.64 95% CI: 0.50-0.82).  Jack-knife analyses showed that removal of 
McBean et al. study and the 2004 Schonberg et al. study, the two studies with the most extreme 
results, from CCI and absolute number of comorbidities groups, respectively, led to insignificant 
decreases in study heterogeneity and no marked change in the summary estimates.  
In addition, nine studies measured individual comorbid conditions and their association 
with screening mammography utilization (Appendix Table S3C).66, 69, 75, 79, 81, 89, 93, 97,102  Physical 
conditions measured included hypertension, diabetes, lung disease, cancer, arthritis, myocardial 
infarction, stroke, heart disease and hip fracture.  Mental conditions measured included 
cognitive impairment, Alzheimer’s disease, depression and psychological distress.  In pooled 
analyses, individual comorbid conditions were not significantly associated with screening 
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mammography utilization (OR: 0.97 95% CI: 0.89-1.06) (Appendix Figure S1).  When stratified 
by type of condition, neither physical conditions (OR: 1.03 95% CI: 0.93-1.14) nor mental 
conditions (OR: 0.85 95% CI: 0.72-1.01) were significantly associated with screening 
mammography utilization.   
Estimates of the effect of functional status on utilization of screening mammography  
 Ten studies measured the effect of functional limitations on screening mammography 
utilization (Figure 2.4), with three studies measuring functional limitations in multiple ways.  Five 
studies measured activities of daily living (ADLs),66, 70, 79,99,100 five studies measured instrumental 
activities of daily living (IADLs),69, 74, 79, 93,96 and three studies used a scale incorporating both 
IADLs and ADLs.69, 96,106  Overall, functional limitations were associated with decreased 
screening mammography utilization (Pooled OR: 0.72 95% CI: 0.62-0.83).  Of the five studies 
measuring ADLs, three calculated odds ratios, showing a significant pooled effect of higher 
number of ADLs on decreased screening mammography utilization (Pooled OR: 0.55 95% CI: 
0.35-0.85) in Figure 2.4. Two studies reported chi-square results comparing screening 
mammography utilization by ADL status (yes/no), with both studies showing a significant 
difference in screening utilization among women experiencing ADL limitations compared to 
women with no ADL limitations 70,100. 
 Among the four studies measuring IADLs, the pooled result showed that higher numbers 
of IADLs were associated with decreased screening mammography utilization (Pooled OR: 0.79 
95% CI: 0.64-0.98).  Three studies measuring IADL limitations in conjunction with ADL 
limitations found inverse associations.69, 96,106  Pooled results indicated that ADL limitations or 
IADL dependency led to decreased screening mammography utilization (Pooled OR: 0.72 95% 
CI: 0.57-0.91). 
In jack-knife analyses, removal of Schootman et al. Long-term ADL and Long-term IADL, 
and Caban et al. findings led to study heterogeneity in ADL (p=0.674), IADL (p=0.106) and 
ADL/IADL (p=0.683) groups being no longer statistically significant, respectively.  However, the 
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pooled estimate still had significant study heterogeneity and did not change appreciably despite 
removal of these studies (p=0.003).  Meta-regression analyses found no significant predictors of 
study heterogeneity.   
Estimates of the effect of health status, life expectancy or prognosis on utilization of 
screening mammography  
 Nine studies measured the association of health status on screening utilization, with 
eight studies measuring perceived general health66, 69, 76, 83, 97,98,106 and two measuring health 
status using the Short Form-12 (SF-12) survey (Appendix Table S5).54,64  The pooled result 
shown in Figure 2.5 demonstrated that lower perceived health was associated with lower 
screening mammography utilization (Pooled OR: 0.80 95% CI: 0.69-0.93).  Jack-knife analyses 
showed no significant decrease in study heterogeneity and meta-regression analyses did not 
find significant predictors of study heterogeneity.   
 Five studies measured prognostic index or life expectancy measures against utilization 
of screening mammography (Appendix Table S5).68, 83, 97, 100,105  The pooled effect of the three 
studies shown in Figure 2.5 measuring life expectancy using regression showed a 
nonsignificant inverse association between life expectancy index score and screening 
mammography utilization (Pooled OR: 0.73 95% CI: 0.53-1.00). 
2.5 DISCUSSION  
Meta-analysis of the studies addressing life expectancy factors and screening 
mammography utilization revealed that older American women with higher numbers of 
functional limitations, higher Charlson Comorbidity Index score and lower perceived health are 
less likely to undergo routine screening mammography.  Prognostic indices, absolute number of 
comorbidities and specific disease conditions were not significantly associated with screening 
mammography utilization.  These observational studies provide a means to understanding how 
different measures of life expectancy affect screening mammography utilization. 
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 While increased CCI score was associated with a decrease in screening mammography, 
the absolute number of comorbidities showed a conflicting, weak positive association with 
screening mammography utilization. It is possible that having more comorbid conditions 
increased women’s contact with their healthcare provider leading to a greater likelihood of using 
preventive care.69,74  Conversely, one study measuring CCI showed no indication that 
physicians had advocated for cancer screening in the population of individuals with diabetes.88 
Other studies noted that there is little time in the primary care clinic to estimate each individual’s 
candidacy for screening, especially older patients with multiple medical problems, which might 
lead physicians to screen everyone to avoid confusion with recommendations or medico-legal 
consequences.54, 74,96 The conflicting results show that more studies need to be conducted to 
determine who should receive screening mammography, and how comorbidity burden should 
factor into a provider’s assessment of who is eligible for screening mammography.  
 Studies consistently indicated that greater numbers of functional limitations decreased 
screening mammography utilization. Studies using scales incorporating ADL limitations (i.e., 
needing help with activities such as showering, dressing, getting in and out of bed/chairs, etc.) 
showed particularly pronounced effects, which might indicate that access factors, such as fewer 
resources and social supports to facilitate travel to and care navigation at mammography 
facilities, may lead to lower utilization rates.66 It is therefore possible that women with ADL 
limitations may need more support to receive mammography utilization.  Another study 
indicated that the strong association found between ADL and IADL (i.e., needing help with 
everyday household chores, shopping, and overall getting around) dependence and 
mammography screening might be indicative of providers considering life expectancy when 
referring women to screening mammography.106  However, the fact that the finding did not occur 
across other measured preventive screenings makes this theory questionable and requires 
further investigation. 
 Poorer self-rated health was also found to be associated with decreased screening 
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utilization, despite some conflicting findings. In one study, pain and discomfort, a potential 
indicator of poorer health, was a common reason why women might decide not to screen.69  
Conversely, a study done by Walter et al. showed that older women with poorer health status, 
measured with the Medical Outcomes Study 12-item Short Form Physical Summary Scale (SF-
12), did not avoid screening.  Although Walter et al. did not have mortality follow-up information 
on the sample, there is strong evidence that life expectancy is limited in women with worst 
health status measured by the SF-12.54   
Pooled analysis of prognostic index scores found no significant association with 
screening mammography utilization, even though some individual studies had significant 
findings. Koya et al. found mammography use significantly associated with four-year mortality 
risk and not age alone, attributing their finding to including age, comorbidity in functional status 
in their measurement of mortality risk.83 They hypothesized that the association means 
clinicians are skilled at identifying predictors of life expectancy in older individuals.83  However, 
findings from other included studies seem to contradict this theory.97,105 
Findings from these studies show that functional limitations and comorbidities when 
measured using the Charlson Comorbidity Index are associated with decreased screening 
mammography utilization, while absolute number of comorbidities was weakly associated with 
increased screening utilization.  When discussing screening mammography with older women, 
providers should ask questions or consult medical records to learn more about these life 
expectancy factors to better assess the potential benefit older women might receive from 
undergoing screening mammography.  Decision aids have been developed in breast cancer 
screening to measure key comorbidity and functional measures, though none have been widely 
implemented.109,110  While more research is necessary to further understand the importance of 
life expectancy in measuring harms and benefits of screening mammography, these findings 
indicate that providers may be weighing more than just age when discussing continuing 
screening mammography with an older woman.  Further assessment of current clinical 
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recommendations and determination of eligibility for screening mammography could lead to 
more accurately tailored screening referrals. 
Strengths and limitations of studies and analysis 
Our systematic review/meta-analysis had key strengths, such as incorporating searches 
from three major research publication databases ensuring full capture of the literature on life 
expectancy factors and screening mammography utilization in older women. The use of quality 
assessment tools allowed us to quantitatively rate the quality of the studies included in our 
analyses. In addition, the use of stratification to clearly review the life expectancy factors 
ensured a limited degree of study heterogeneity when measuring our various exposures and 
screening mammography utilization.  Our study also was able to leverage meta-regression in 
sensitivity analyses to learn more about how different study features contributed to 
heterogeneity found in pooled results from meta-analyses. 
Our review also had several limitations.  The 20-year timespan of systematic review 
could lead to varied results due to secular trends but examining the study results by year does 
not indicate that a trend exists.  While this might account for some variation in the results, the 
lack of significant changes in screening mammography guidelines or public outreach within this 
older age group make any difference in effects due to secular trends minimal.  Of the 25 studies 
included in our analysis, 17 relied on self-reported information for measurement of the 
exposure, while 16 relied on self-reported information to measure screening mammography 
utilization.  This raises concerns about recall bias, particularly when citing screening utilization 
within the last two to five years.  Furthermore, self-reported health status is not a precise 
measurement of an individual’s health, as it uses a Likert scale to assess health at the instance 
of interview, which might not represent an individual’s overall health outside of the clinical 
environment.  Studies that ascertained screening utilization through insurance claims66, 68, 73, 76,77, 
79, 88,89,100,101 were unable to distinguish between mammograms undertaken for screening and 
diagnostic purposes. However, it is reasonable from a clinical perspective to assume that the 
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majority were screening procedures, since diagnostic procedures are performed only when a 
woman presents with symptoms of breast cancer.66,88,89  The inability to distinguish the two 
types of mammography might lead to the measured population being slightly sicker than the 
normal screening mammography population, which would lead to an overestimate of 
association. 
 More than half of the studies included were cross-sectional by design, which restricts the 
ability to ensure temporality of the exposure/outcome relationship.  Despite this concern, all but 
two studies were of moderate to excellent study quality based on our cross-sectional study-
specific quality assessment using the Newcastle-Ottawa Survey.    
2.6 CONCLUSION 
Studies have shown that the primary determinant of screening with mammography, 
regardless of age, is a physician’s recommendation.96,111–113  It is therefore critical that the 
guidelines be updated to reflect the importance of characteristics such as the presence of 
severe functional dependencies in activities of daily living and severe comorbidity as caused by 
conditions such as end-stage renal disease, severe dementia in concert with clinical judgment 
to estimate an individual’s potential risks and benefits from screening rather than basing 
screening decisions on age alone. This systematic review and meta-analysis show that 
consideration of functional status and comorbidity might be occurring in practice, but still needs 
to be further weighed in screening mammography recommendations, and targeted interventions 
are needed to facilitate precision cancer screening. 
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Figure 2.2: PRISMA Flowchart of Included Studies 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 
 
For more information, visit www.prisma-statement.org. 
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2.7.1 PubMed Search Strategies 1991-2016, English articles 
#1 
 ((“breast cancer” [tiab] OR “breast neoplasms” [mh] OR "breast tumor" [tiab] OR "breast 
tumors" [tiab] OR "breast tumour" [tiab] OR "breast tumours" [tiab] OR breast diseases [mh]) 
AND (mass screening [mh] OR screening [tiab] OR screened [tiab] OR screen [tiab])) OR 
“breast cancer screening” OR mammography [tiab] OR mammogram* [tiab] OR mammography 
[mh]  
#2 
comorbidity [mh] OR comorbidities [tiab] OR comorbid [tiab] OR “co morbidity” [tiab] OR “co 
morbidities” [tiab] OR multimorbidity [tiab] OR multimorbidities [tiab] OR “daily life activity” [tiab] 
OR “activities of daily living” [mh] OR “disabled persons” [mh] OR disabled [tiab] OR disability 
[tiab] OR disabilities [tiab] OR “functional assessment” [tiab] OR “functional disease” [tiab] OR 
“functional diseases” [tiab] OR “functional impairment” [tiab] OR “functional limitation” [tiab] OR 
“health status” [mh] OR “health status” [tiab] OR “mobility impairment” [tiab] OR “motor 
dysfunction” [tiab] OR “motor impairment” [tiab] OR “motor limitation” [tiab] OR  “physical 
disability” [tiab] OR “physical disease” [tiab] OR “physical diseases” [tiab] OR “physical 
impairment” [tiab] OR “physical limitation” [tiab] OR “physical functioning” [tiab] OR “walking 
difficulty” [tiab] OR alcoholism [mh] OR alcoholic [tiab] OR alcoholics [mh] OR “Alzheimer 
disease” [mh] OR Alzheimer’s [tiab] OR dementia [mh] OR dementia [tiab] OR arthritis [mh] OR 
arthritis [tiab] OR asthma [mh] OR asthma [tiab] OR “cardiovascular disease”  [tiab] OR 
“cardiovascular diseases” [tiab] OR “cardiovascular diseases” [mh] OR stroke [mh] OR stroke 
[tiab] OR “cerebrovascular disease” [tiab] OR “chronic arthritis” [tiab] OR “chronic bronchitis” 
[tiab] OR “bronchitis, chronic” [mh] OR “chronic disease” [mh] OR “chronic diseases” [tiab] OR 
“chronic disease” [tiab] OR “chronic illness” [tiab] OR “chronically ill” [tiab] OR “terminally ill” [mh] 
OR “terminally ill” [tiab] OR “chronic condition” [tiab] OR “chronic conditions” [tiab] OR “chronic 
hepatitis” [tiab] OR “hepatitis, chronic” [mh] OR “chronic inflammation” [tiab] OR  “renal 
insufficiency, chronic” [mh] OR “chronic kidney disease” [tiab] OR “chronic kidney diseases” 
[tiab] OR “kidney failure, chronic” [mh] OR “chronic kidney failure” [tiab] OR “chronic kidney 
failures” [tiab]  OR “pulmonary disease, chronic obstructive” [mh] OR COPD [tiab] OR “chronic 
obstructive pulmonary disease” [tiab] OR “chronic respiratory failure” [tiab] OR “cognitive defect” 
[tiab] OR “cognitive defects”[tiab] OR “cognitive impairment” [tiab] OR “cognitive impairments” 
[tiab] OR “cognitive decline” [tiab] OR “cognitive declines” [tiab] OR “cognition disorders” [mh] 
OR “cognition disorders” [tiab] OR “cognition disorder” [tiab] OR depression [mh] OR depression 
[tiab] OR “depressive disorder” [mh] OR “depressive disorders” [tiab] OR “depressive disorder” 
[tiab] OR “diabetes mellitus” [mh] OR diabetes [tiab] OR diabetic [tiab] OR diabetics [tiab] OR 
renal dialysis [mh] OR dialysis [tiab] OR “myocardial infarction” [mh] OR “heart attacks” [tiab] 
OR “heart attack” OR “heart disease” [tiab] OR “heart diseases” [mh] OR hypertension [mh] OR 
hypertension [tiab] OR “life expectancy” [mh] OR “life expectancy” [tiab] OR “liver diseases” [mh] 
OR “liver diseases” [tiab] OR “liver disease” [tiab] OR “mental disorders” [mh] OR “mental 
disorder” [tiab] OR “mental disorders” [tiab] OR “mental diseases” [tiab] OR “mental disease” 
[tiab] OR “lung diseases” [mh] OR “lung diseases” [tiab] OR “pulmonary diseases” [tiab] OR 
“pulmonary disease” [tiab] OR “serious health events” [tiab] 
#3 
Aged [mh] OR aged [tiab] OR elderly [tiab] OR “aged, 80 and over” [mh] OR “frail elderly” [mh] 
OR age factors [mh] OR “age factors” [tiab] OR “age factor” [tiab] 
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#4 (430 articles) 
#1 AND #2 AND #3 Filters: Publication date from 1991/01/01 to 2016/10/25; English 
 
2.7.2 EMBASE (Elsevier) search strategies 1991-2016 English articles 
  
#1 
(( 'breast tumor'/de OR 'breast cancer'/de OR breast NEAR/3 cancer OR ‘breast cancer’:ab,ti) 
AND ('cancer screening'/de OR 'mass screening'/de OR 'screening'/de OR screen OR screened 
OR screening)) OR ‘breast cancer screening’:ab,ti OR 'mammography'/de OR 
mammogram:ab,ti OR mammograms:ab,ti OR mammography:ab,ti 
#2 
Comorbidity/de OR comorbidity:ab,ti OR comorbidities:ab,ti OR comorbid:ab,ti OR 'co 
morbidity':ab,ti OR 'co morbidities':ab,ti OR 'co morbid':ab,ti OR multimorbid* OR multi NEXT/1 
morbid* OR age:ab,ti OR 'daily life activity'/de OR disabled OR 'disabled person'/de OR 
'disability'/mj OR disability:ab,ti OR disabilities:ab,ti OR 'functional assessment'/mj OR 
'functional disease'/de OR functional NEAR/3 (impairment* OR limitation* OR mobilit* OR 
status) OR mobility NEAR/3 (impairment* OR limitation*) OR 'motor dysfunction'/de OR motor 
NEAR/3 (impairment* OR limitation*) OR 'physical disability'/de OR 'physical disease'/mj OR 
physical NEAR/3 (impairment* OR limitation*) OR 'physical functioning' OR 'walking difficulty'/de 
OR 'alcoholism'/de OR alcoholic OR alcoholics OR 'alzheimer disease'/de OR alzheimer* OR 
arthritis:ab,ti OR asthma:ab,ti OR 'cardiovascular disease'/mj OR 'cardiovascular disease':ab,ti 
OR 'cardiovascular diseases':ab,ti OR 'cerebrovascular accident'/mj OR 'cerebrovascular 
disease'/mj OR 'chronic bronchitis' OR 'chronic condition' OR 'chronic conditions' OR 'chronic 
disease' OR 'chronic diseases' OR 'chronic hepatitis' OR 'chronic illness' OR 'chronic illnesses' 
OR 'chronic inflammation'/de OR 'chronic kidney disease' OR 'chronic kidney diseases' OR 
'chronic kidney failure' OR 'chronic kidney failures' OR 'chronic obstructive lung disease'/de OR 
'chronic obstructive lung diseases' OR 'chronic patient'/de OR 'chronic respiratory failure'/de OR 
'chronically ill' OR copd:ab,ti OR 'cognitive defect' OR 'cognitive defects' OR 'cognitive 
impairment' OR 'cognitive impairments' OR 'cognitive decline' OR 'cognitive declines' OR 
'cognition disorder' OR 'cognition disorders' OR 'cognitive disorder' OR 'cognitive disorders' OR 
'cognitive status' OR 'dementia'/de OR dementia:ab,ti OR 'depression'/de OR 'diabetes 
mellitus'/de OR diabetes:ab,ti OR diabetic*:ab,ti OR 'dialysis'/de OR dialysis:ab,ti OR 'heart 
attack':ab,ti OR 'heart disease'/de OR 'heart disease':ab,ti OR 'heart diseases':ab,ti OR 'health 
status'/de OR ‘health status’:ab,ti OR 'hypertension'/de OR hypertension:ab,ti OR 'heart 
infarction'/de OR 'myocardial infarction':ab,ti OR 'kidney disease'/de OR 'kidney failure':ab,ti OR 
'late life depression'/de OR ‘late life depression’:ab,ti OR 'life expectancy'/de OR ‘life 
expectancy’:ab,ti OR 'liver disease'/mj OR ‘liver disease’:ab,ti OR ‘liver diseases’:ab,ti OR 'lung 
disease'/mj OR ‘lung disease’:ab,ti OR ‘lung diseases’:ab,ti OR 'major depression'/de OR 
depression:ab,ti OR 'mental disease'/mj OR ‘mental disease’:ab,ti OR ‘mental diseases’:ab,ti 
OR obese:ab,ti OR 'obesity'/de OR obesity:ab,ti OR stroke:ab,ti OR stroke/de OR ‘frail 
elderly’/de OR ‘frail elderly’:ab,ti  
 
# 3      
 47 
Aged/exp OR aged:ab,ti OR elderly:ab,ti OR ‘very elderly’/de OR older:ab,ti OR ‘age 
factors’:ab,ti OR ‘age factor’:ab,ti OR age:ti 
 
#4 
#1 AND #2 AND #3 AND [article]/lim AND [english]/lim AND [1991-2016]/py 
#5 
mammography OR mammogram OR mammograms OR 'breast cancer screening' AND (aged 
OR older OR elderly) 
#6 
utilization:ti,ab  OR utilization:ti,ab OR use:ti OR stress OR anxiety OR distress OR harm OR 
harms OR benefit* OR 'false positive' OR 'upper age limit' OR 'over diagnosis' OR 'stage of 
diagnosis' OR outcome OR outcomes OR 'decision making' OR mortality OR 'life expectancy' 
OR ‘quality adjusted life expectancy’  OR ‘risk assessment’ OR ‘gain one life year’ OR age:ti  
OR discontinuation 
#7 
‘co morbidity’ OR ‘co morbidities’ OR comorbid OR comorbidity OR comorbidities OR 'functional 
impairment'/exp OR 'functional impairment' OR 'functional impairments' OR 'disability'/exp OR 
disability OR 'health status'/exp OR 'health status' OR 'intellectual impairment' OR 'intellectual 
impairments' OR 'quality of life' OR 'chronic disease' OR 'terminally ill' OR limitation OR age:ti  
#8  
#5 AND #6 AND #7 AND [article]/lim AND [english]/lim AND [1991-2016]/py 
#9 
#4 OR #8  
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3. CHAPTER 2: Factors that influence radiation doses used for lung cancer 
screening: Analysis of data from a large US dose registry 
Joshua Demb, Philip Chu MS, Sophronia Yu, Robin Whitebird PhD, Leif Solberg PhD, 
Diana L. Miglioretti PhD, Rebecca Smith-Bindman MD 
 
 
Figure 3.1: Conceptual Framework for Multilevel Factors Involved in Cancer Screening, 
Multilevel Factors for Chapter 2 Highlighted 
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3.1 ABSTRACT 
Importance: The American College of Radiology (ACR) has targeted radiation doses for lung 
cancer screening (LCS) computed tomography (CT). Without standard protocols, doses could 
be unnecessarily high, reducing screening benefits.  
Objective: Characterize LCS radiation doses and identify factors explaining variation. 
Design, Setting, Participants: Prospectively collected LCS exam dose metrics, 2016-2017, 
from 74 US institutions in the University of California, San Francisco CT Radiation Dose 
Registry.   
Main Outcomes and Measures: Log-transformed measures of: (1) mean volume computed 
tomography dose index (CTDIvol, mGy), average dose per slice and (2) mean effective dose 
(ED, mSv), total dose received, reflecting number of scans and estimated future cancer risk. 
Also measured (3) proportion of exams above ACR benchmarks (CTDIvol ≤3 mGy, ED ≤1 
mSv); and (4) proportion of exams above 75th percentile of registry doses (CTDIvol ≤2.7 mGy, 
ED ≤1.4 mSv). Institution-level factors, as predictors, were collected through baseline survey. 
Mixed-effects linear and logistic regression models were estimated using forward variable 
selection. Results are percentage excess dose and odds ratios (ORs) with 95% confidence 
intervals (CIs).     
Results: Of 74 institutions, 19 (26%) had median CTDIvol and 54 (73%) had median ED higher 
than ACR guidelines. Institutions allowing any radiologists to establish protocols had 44% higher 
mean CTDIvol (mean dose difference [MDD]: 44%; 95%CI: 19-69%) and 26% higher mean ED 
(MDD: 26%; 95%CI: 4-49%) compared to limiting who establishes protocols. These institutions 
had higher odds of exams exceeding ACR CTDIvol guidelines (OR: 10.8; 95%CI: 2.0-58.1), and 
75th percentile of registry CTDIvol (OR 10.6; 95%CI: 1.8-63.8) or ED (OR 7.04; 95%CI: 1.5-
32.2). Having only lead radiologists establish protocols resulted in lower odds of doses 
exceeding ACR ED guidelines (OR 0.04; 95%CI: 0.01-0.29). Having external rather than 
internal medical physicists was associated with increased odds of exceeding ACR CTDIvol 
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guidelines (OR: 4.7; 95%CI: 1.5-14.9) and 75th registry percentile (OR 8.2; 95%CI: 2.3-29.4). 
Institutions reporting protocol updates as needed had 22% higher mean CTDIvol (MDD: 22%; 
95%CI: 3%-40%). 
Conclusion and Relevance: Facilities varied in LCS CT-dose distributions. Institutions that 
limited protocol creation to lead radiologists and had internal medical physicists had lower 
doses.  
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3.2 INTRODUCTION 
Few explicit standards exist for the radiation doses to use for computed tomography 
(CT) scans. Several organizations including the American College of Radiology (ACR) promote 
performing CT scans using the “as low as reasonably achievable” principle for radiation doses. 
However, the lack of specific guidelines and established standards for the numerous types of 
CT examinations results in doses variation within and across institutions.114–118 Institutional 
decisions, such as about use of multiphase scanning, and choices about technical parameters 
can result in large differences in radiation doses that patients receive.116,119 Further, little data 
explores institution-level factors that could influence CT doses.  
 One protocol receiving increased focus is low-dose CT for lung cancer screening (LCS). 
LCS must balance the potential for earlier cancer detection through screening with concerns 
about false positives, invasive work-ups and increased cancer risk from CT radiation 
exposure.120–124 LCS is beneficial when low-dose techniques are used but not when higher CT 
doses—similar to those used for routine chest CT scans—are used, because radiation from 
higher doses may cause almost as many cancers as are detected early by screening.125  
 As part of Centers for Medicare and Medicaid Services (CMS) requirements for LCS 
reimbursement, institutions must use low-dose techniques and participate in a dose registry. 
The ACR recommends that LCS scans have a volume computed tomography dose index 
(CTDIvol) of 3 mGy and an effective dose (ED) of 1 mSv.126–130 Although variation in LCS doses 
is reported,131,132 the proportion of patients receiving appropriately low-dose exams is unknown. 
Further, no study identified factors associated with optimum low-dose performance.   
 This study identified factors associated with CT dose variation among institutions 
participating in a large CT radiation-dose registry. We assessed how often patients received 
appropriate low-dose LCS examinations according to ACR guidelines and identified institution-
level factors associated with high CT radiation doses. Identifying institution-level factors will help 
facilities performing CT scans avoid unnecessary variation in LCS CT doses.  
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3.3 METHODS 
CT Radiation Dose Registry  
 In 2015, we established an international CT radiation dose registry at the University of 
California, San Francisco to collect radiation doses for CT exams on consecutive patients from 
150 institutions in the United States and seven other countries. All institutions participating in the 
registry use the same radiation dose-monitoring software (Radimetrics, Bayer, Whippany, NJ), 
enabling data sharing within the registry using HIPAA-compliant tools. For the Partnership for 
Dose trial (NIH NCI R01-CA181191), a National Institutes of Health-funded pragmatic 
randomized comparative effectiveness study on approaches to optimizing radiation doses for 
routine head, chest, abdomen, and combined chest and abdomen CT exams, we surveyed 
institutions prior to trial start about characteristics including how they perform and oversee CT. 
Data from the organizational survey and the dose registry were combined to assess 
relationships between institutional characteristics and radiation dose. 
Inclusion/Exclusion 
 Only US institutions that performed a minimum 24 LCS scans during the study period 
(2016-2017) and returned a completed survey were included (N=74). Because LCS is 
recommended for patients aged ≥40 with risk factors for cancer (e.g., ≥30 pack-year smoking 
history and current smoking or quitting <15 years ago), analyses were limited to patients aged 
≥40. We could not determine patients’ smoking history, which is an eligibility requirement for 
insurance coverage of LCS scans. Non-US institutions were excluded because their CT LCS 
scans are not subject to the ACR LCS guidelines. 
Organizational Survey Predictors and Scan Covariates 
 All institutions eligible for our study completed the organizational survey, which was 
required to participate in the Partnership for Dose trial. The survey asked about structural and 
organizational aspects of the institution’s CT imaging workflow that might be associated with 
radiation dose, including type of facility and role of individuals who establish and modify CT 
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protocols, which are the instructions that technologists use to program CT scanners. Protocols 
vary by reasons for scans and by institution. The survey also asked: 1) the type of institution, as 
academic/teaching hospital, trauma center (Level 1, 2, or 3), public hospital, community 
hospital, private hospital, acute care facility, primary care institution, pediatric hospital, tertiary 
referral hospital, or outpatient imaging institution (not mutually exclusive); 2) if a medical 
physicist was involved in creating protocols and if so, if the physicist was employed by the 
organization on staff or external; 3) individual(s) who established or altered protocols for the 
institution (manufacturer, organizational leadership, organization-level medical physicist, site-
level medical physicist, radiology site, lead radiologists, any individual radiologists, head 
technologist, technologists performing exams, or other individuals, not mutually exclusive); 4) 
frequency at which protocols were updated (as needed, less than yearly, yearly or more than 
yearly); and 5) if protocols were locked, meaning unchangeable after being established 
(yes/no).  Of the 150 institutions in the registry, 116 completed the organizational survey (77% 
response rate). 
We included patient-level factors in all analyses including age, sex, and chest diameter 
(to account for patient size).  
Outcomes 
 We evaluated two measures of dose, CTDIvol and ED. CTDIvol reflects the average 
radiation dose output per standardized volume, typically described as dose per slice in mGy. ED 
is the total dose output of the scanner (dose per slice x length scanned or total number of slices) 
weighted by organ sensitivity in anatomic scan region to represent the future risk of cancer from 
this exposure in mSv. Choices made by technologists performing scans directly influence both 
CTDIvol and ED. While LCS should include only single CT scans, multiple CT scans may be 
performed, for example for diagnostic CT. Multiple scans would be reflected only in ED, not 
CTDIvol measures, since average dose per slice does not vary by number of scans.  
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ACR and CMS guidelines for LCS specify doses of ≤3.0 mGy for CTDIvol and ≤1 mSv 
for ED for a standard patient defined as 170 cm and 70 kg with a body mass index of 24.3. 
Because these doses are about 15%-50% lower than doses used for standard chest CT,133,134 
LCS scans are described as low-dose CT. Doses for LCS CT vary by patient size: patients who 
are larger or smaller than the standard size receive doses slightly above or below guideline 
thresholds. We accounted for dose variation by size by adjusting doses using average chest 
diameters measured on CT images. We calculated the 75th percentile of the distribution of 
radiation doses in the registry and defined doses above this percentile as high dose. To account 
for the non-normal nature of the CTDIvol and ED measures, these variables were log-
transformed for incorporation into linear models.   
Statistical Analysis 
 We assessed facility-level distributions of CTDIvol and ED for LCS scans using boxplots, 
adjusted for chest diameter by standardizing facility-level doses by median facility-level chest 
diameter. We used mixed-effects linear regression models to evaluate predictors associated 
with adjusted CT dose levels.135 We included facility-level and machine-level random effects to 
account for correlation among exams performed on the same machine or at the same facility. 
Variables included in models were selected using forward selection. After models were 
selected, coefficients were exponentiated to calculate excess percentage of dose, with 
corresponding 95% confidence intervals (CIs). Mixed-effects logistic regression with forward 
selection was used to evaluate associations between institutional factors and having doses 
above ACR guidelines and the 75th percentile benchmark. Statistical analyses were performed 
using SAS 9.4 (SAS Corporation, Cary, NC).   
3.4 RESULTS 
Data were for 12,771 LCS CT scans performed at 74 institutions (Table 3.1). Overall, 
58% of participants were male, and the median age was 65 years (interquartile range [IQR]: 60-
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70). The mean ED for LCS adjusted for chest diameter was 1.9 mSv (standard deviation [SD]: 
2.4 mSv) and the mean CTDIvol adjusted for patient size was 2.4 mGy (SD: 2.0 mGy). 
Unadjusted values were 1.3 mSv (SD 1.6 mSv) for ED and 2.3 mGy (SD: 2.0 mGy) for CTDIvol. 
Distributions of adjusted CTDIvol and ED are in Figures 3.2 and 3.3. We found 19 institutions 
(26%) with a median adjusted CTDIvol value higher than the ACR guideline of 3 mGy (median: 
2.4, IQR: 1.5-2.7) and 54 (73%) with a median adjusted ED higher than the ACR guideline of 1 
mSv (median: 1.1 mSv, IQR: 0.7-1.5). Of all CT scans, 51% had an ED higher than ACR 
guidelines and 20% had a CTDIvol higher than guidelines. The results did not appreciably 
change when we used unadjusted values to characterize the number of institutions and patients 
whose doses exceeded guidelines. 
 Institutional responses to the organizational survey are in Table 3.2. Most (59%) 
institutions reported serving as outpatient imaging facilities, with lead radiologists (86%) or a 
head technologist (49%) establishing scan protocols. Technologists performing exams were the 
most likely to alter scan protocols (32%) compared to other personnel. The most common 
method of reviewing protocols was reported as “as needed” (49%).   Most institutions (59%) lock 
their protocols after they are established. 
Predictors of CTDIvol 
Predictors of CTDIvol levels by CT scan type are in Table 3.3. Doses and likelihood of 
exceeding benchmarks increased with patient size and doses were higher among women, 
although differences were not large.   
 CT scans performed at private hospitals were associated with greater odds of a high-
dose exam (odds ratio [OR]: 49.5, 95%CI: 1.9-1280), though the sample size was inadequate 
for inferring an effect. When the medical physicist was external instead of being on staff at the 
institution, doses were higher (OR for exceeding ACR benchmarks: 4.7, 95%CI: 1.5-14.9; OR 
for exceeding 75th percentile: 8.2, 95%CI: 2.3-29.4). For institutions reporting that any 
radiologist could establish protocols, doses were also higher (44% higher mean dose; 95%CI: 
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19%-69%; OR for a study exceeding ACR guidelines: 10.8, 95%CI: 2.0-58.1; OR for exceeding 
75th percentile benchmark: 10.6, 95%CI 1.8-63.8). Institutions reporting that only lead 
radiologists altered protocols had a 27% lower CTDIvol (95%CI: -53% to -1%). Institutions that 
updated protocols “as needed” had higher average doses (22% higher dose, 95%CI: 3%-40%). 
Predictors of ED 
Significant ED predictors are in Table 3.4 and are similar to CTDIvol predictors. Age, 
gender and chest diameter were significant ED predictors. Having any individual radiologist 
establish protocols was associated with higher doses (26% excess effective dose, 95%CI: 4%-
49%; OR for exceeding 75th percentile benchmark: 7.04, 95%CI: 1.54-32.2). Having only the 
lead radiologist (OR: 0.04, 95%CI: 0.01-0.29) or technologist performing exams (OR: 0.12, 
95%CI: 0.02-0.85) responsible for establishing protocols led to lower odds of exceeding ACR 
effective dose guidelines. Having any type of medical physicist (OR: 0.23, 95%CI: 0.08-0.69) 
establish the LCS CT protocol led to decreased odds of exceeding the 75th percentile 
benchmark.   
3.5 DISCUSSION 
Overall, we found wide variation in the distribution of LCS CT doses across facilities 
participating in our study, despite defined ACR guidelines. We found that 73% of participating 
institutions had median EDs for LCS scans that exceeded ACR guidelines, with a significant 
number of patients receiving doses above benchmarks created to ensure low radiation-dosage 
exams. ED reflects doses used for imaging and can indicate future cancer risk resulting from 
these studies. Over half of patients received doses above ACR targets after accounting for 
patient size, measured using chest diameter. If LCS CT exams are not performed using low-
dose techniques, potential screening benefits and margins of benefits over risks are reduced.132 
While the risk of radiation-induced cancer and resultant risk of mortality is low compared to the 
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benefits of LCS using low-dose techniques, the risk of radiation-induced cancer rises in parallel 
with doses used.   
 We identified several institution-level factors associated with using doses higher than 
needed. The magnitude of associations was as high as 44%, and the identified factors 
increased the odds of a high-dose exam by as much as 50-fold. The factors that were most 
predictive of high doses included allowing individual radiologists to establish protocols, having 
an external rather than an internal staff medical physicist, being a private hospital, and updating 
protocols as needed instead of yearly. While we cannot establish causality in this observational 
study, our results suggest that considering these factors (for example, allowing only lead 
radiologists to establish protocols) could have a meaningful impact on dose, and could be 
important areas to develop interventions to optimize doses of CT protocols.   
The inclusion of any individual radiologists in protocol establishment led to markedly 
higher odds of increased radiation dose. A potential cause of this finding could be the lack of 
training on dose optimization and motivation to change in some radiologists.136–140 Specifically, 
radiologists may not believe CT radiation risk is particularly concerning, may prefer that people 
not involved in reading scans alter protocols, or prefer the image quality available in higher-dose 
diagnostic CT scans rather than the lower quality of LCS.140 Ways to improve dose levels in 
institutions where individual radiologists establish protocols may include: ensuring that 
radiologists are aware of the current CT scan guidelines and the potential for harmful effects 
related to dose, particularly for standardized protocols such as LCS; and providing feedback to 
radiologists on the doses they use, which is currently not standard practice.   
 Having an on-staff medical physicist led to an institution having significantly decreased 
odds of scans with high CTDIvol compared to institutions with medical physicists who are 
outside consultants or employed by a CT manufacturer. Similarly, odds of ED exceeding the 
75th percentile benchmark were lower when any medical physicist, internal or external to the 
institution, was involved in establishing protocols. Given that medical physicists are trained to 
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focus on safe, effective application of radiation in medical imaging, having a medical physicist 
on staff at an institution and actively involved in CT protocol development may help radiologists 
better manage CT radiation doses;141 our data supported this possibility. On-staff medical 
physicists may provide quality control more closely or more frequently. External medical 
physicists may focus more on phantom studies and less on reviewing doses for examination 
subtypes such as LCS. Furthermore, as medical physicists are responsible for monitoring a 
practice’s doses against national benchmarks, having a medical physicist onsite instead of 
contracted for annual or less frequent visits may better ensure that institutions maintain 
appropriate radiation dose levels.141 
Involving technologists who perform exams in protocol establishment process also led to 
lower odds of EDs higher than ACR guidelines. Interestingly, no association was seen with 
CTDIvol levels, meaning that in general, technologists who established protocols used shorter 
scan lengths or used single rather than multiple CT scans more often. Technologists may be 
less sensitive to image quality than radiologists, as technologists do not interpret scans.  
Being able to modify protocols can lead to lowering doses at some institutions, but can 
also lead to higher doses.142 Our results indicated that the type of personnel involved in 
establishing protocols may have a profound impact on CT radiation doses delivered. Allowing 
any individual radiologist to adjust protocols tended to result in higher doses, whereas having 
lead radiologists manage protocol adjustment may lower doses. Given the clear guidelines for 
low-dose LCS, having fewer individuals involved in scan protocols may avoid unnecessary 
variation in radiation doses.  Future studies should further investigate the effects of limiting 
personnel involved in protocol development on CT scan radiation dose levels. 
 Our study has several strengths, including employing data from the largest trial of CT 
scan radiation doses to date, using data from a wide variety of types of institutions performing 
CT scans, and including random effects to account for institution-level and scanner-level 
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variation. Analyses also adjusted for key, individual-level scan factors such as age, gender and 
patient diameter, which can slightly affect resultant radiation doses.   
Our study had several limitations. Since we measured only LCS scans and resultant 
radiation doses, we did not follow individuals longitudinally to assess the relationships among 
CT dose and lung cancer detection or resultant effects on reducing mortality. These data would 
be informative for learning how exposures affect long-term outcomes. Our survey relied on self-
reporting by leaders at participating facilities. These leaders were responsible for providing 
responses that represented practices throughout their institution but could be biased and reflect 
aspirational goals rather than current practice. To ensure that responses were representative of 
their facility, leaders were asked to contact institutional medical physicists, technologists and 
radiologists. Data were collected during a trial to optimize CT doses. However, the trial was not 
focused on LCS and we did not see changes in LCS during the trial.  
We identified LCS CT by finding scans that were indicated as LCS in their protocol name 
or study description. Some scans might have been misclassified as LCS scans, which could 
lead to misrepresentation of radiation dose distributions within an institution. However, we 
thoroughly reviewed our sorting methodology and performed sensitivity analyses to account for 
potential misclassification, and our findings were robust to these concerns. Our statistical 
analyses measured institution-level factors while clustering at the facility and machine levels; 
thus, some estimates from mixed models have wide standard errors due to small sample sizes 
for some institutions and machines. Lastly, we did not determine if patients were appropriate 
candidates for LCS based on risk factors such as smoking history.   
3.6 CONCLUSION 
 Among institutions performing low-dose CT scans for LCS, a significant proportion of 
institutions and patients exceeded guideline-recommended dose levels. Institutional 
characteristics such as allowing any individual radiologists to establish CT scan protocols, 
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updating protocols as necessary rather than annually or at other fixed times, and being a private 
hospital were associated with likelihood of higher radiation doses than other institutions. 
Conversely, having on-staff medical physicists, lead radiologists, technologists performing 
exams, or any medical physicists responsible for establishing protocols was associated with 
lower radiation doses. These findings indicated that dose-optimization practices may benefit 
from being tailored to specific practice types, as well as different organizational structures, to 
have a higher likelihood of meeting dose guidelines. 
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Table 3.1: Characteristics of all low-dose CT lung cancer screening scans 
 Lung Cancer Screening 
Number of Scans (Average/Facility) 12,771 (173) 
Age, Median (IQR) 65 (60, 70) 
Gender, % Male  58% 
Effective Dose (mSv)  
Unadjusted for Patient Diameter  
Mean (SD) 1.3 (1.6) 
Median (IQR) 1.0 (0.7, 1.4) 
Adjusted for Patient Diameter  
Mean (SD) 1.9 (2.4) 
Median (IQR) 1.4 (1.0, 1.9) 
CTDIvol (mGy)  
Unadjusted for Patient Diameter  
Mean (SD) 2.3 (2.0) 
Median (IQR) 2.0 (1.3, 2.7) 
Adjusted for Patient Diameter  
Mean (SD) 2.4 (2.0) 
Median (IQR) 2.1 (1.5, 2.7) 
CT, computed tomography; IQR, interquartile range; SD, standard deviation, CTDIvol, 
volume computed tomography dose index; ACR, American College of Radiology 
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Table 3.2: Institutional Characteristics 
 
Institutions that Perform 
Lung Cancer Screening  
(N=74) 
N (%) 
Institution Type within Organization  
(choose all that apply)  
Academic/Teaching Hospital 15 (20) 
Trauma Center 17 (23) 
Public Hospital 10 (14) 
Community Hospital 19 (26) 
Private Hospital 3 (4) 
Acute Care Facility 18 (24) 
Primary Cancer Facility 13 (18) 
Pediatric Hospital 4 (5) 
Tertiary Referral Hospital 7 (9) 
Outpatient Imaging Facility 44 (59) 
Medical Physicist Type  
External Consultant  34 (48) 
Who Establishes Protocols (choose all that apply)  
Manufacturer 14 (19) 
Organizational Leadership 8 (11) 
Medical Physicist - One for the Organization 20 (27) 
Medical Physicist - At Particular Site 0 (0) 
Radiology Site 14 (19) 
Lead Radiologists 64 (86) 
Any Individual Radiologists 9 (12) 
Head Technologist 36 (49) 
Technologists Performing Exams 10 (14) 
Other 4 (5) 
Who Alters Protocols (choose all that apply)  
Manufacturer 2 (3) 
Organizational Leadership 2 (3) 
Medical Physicist - One for the Organization 3 (4) 
Medical Physicist - At Particular Site 1 (1) 
Radiology Site 3 (4) 
Any individual Radiologists 9 (12) 
Lead Radiologists 9 (12) 
Head Technologist 22 (30) 
Technologists Performing Exams 24 (32) 
Other 1 (1) 
How Frequently are Protocols Updated?  
As Needed 36 (49) 
Less Than Yearly 11 (15) 
Yearly 25 (34) 
More Than Yearly 2 (3) 
Are the Protocols Locked?  
Yes 44 (59) 
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Chapter 3: The impact of employment change on screening mammography 
utilization during the U.S. Great Recession: The Health and Retirement Study 
Joshua Demb MPH, Isabel E. Allen PhD, Robert A. Hiatt MD, PhD,  
Dejana Braithwaite PhD 
 
 
Figure 4.1: Conceptual Framework for Multilevel Factors Involved in Cancer Screening, 
Multilevel Factors for Chapter 3 Highlighted 
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4.1 ABSTRACT 
INTRODUCTION: Despite recent efforts to improve access to cancer screening, major 
structural events at a societal level may radically impact screening behaviors. Between 2007 
and 2009, the Great Recession in the United States led to spikes in unemployment nationwide 
and left many low and middle-income families uninsured due to an acute decrease in employer-
sponsored health insurance. These changes in employment and employer-sponsored insurance 
could have exacerbated existing inequalities in cancer screening access.  
METHODS: Using data from 2002-2012 in the longitudinal, population-based Health and 
Retirement Study (HRS), we assessed how individual-level employment status affected 
screening mammography utilization during the Great Recession, potential variation by insurance 
access or race/ethnicity, and temporal trends. Multilevel models accounted for state-level 
factors as random intercepts and study year as random slopes.  
RESULTS: The HRS study population of 8,512 women ages 50-64 was weighted to represent 
the general US population. Rates of screening mammography were 77% in 2004, 76% in 2008 
and 69% in 2012. At baseline, 38% of women had full-time employment and only 3% of women 
were unemployed.  From 2002 to 2012, proportions of uninsured women increased from 20% to 
27%.  Part-time employment (OR: 0.80, 95%CI: 0.70-0.92), unemployment (OR: 0.76, 95%CI: 
0.60-0.97) and other employment status (disability or out of work force) (OR: 0.79, 95%CI: 0.68-
0.91) were associated with decreased screening mammography utilization.  Our findings also 
showed being uninsured was significantly associated with reduced odds of screening utilization 
(OR: 0.46, 95% CI: 0.39-0.53).  There was significant interaction between insurance status and 
employment status (p<0.01), with uninsured women having lower predicted probability of 
screening mammography utilization compared to insured women across all employment status 
groups.   
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CONCLUSION: Part-time employment, unemployment, and being disabled or out of the work 
force (“other” employment) decreased odds of screening mammography utilization.  
Furthermore, uninsured women had significantly lower likelihood of screening mammography 
utilization compared to insured women.  Future research should further clarify the role of 
employment and insurance status in screening utilization. 
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4.2 INTRODUCTION 
 Breast cancer accounts for 30% of cancer incidence and is the second leading cause of 
cancer death among women in the United States (US).3 Screening mammography, the only 
population-based method for early detection of breast cancer, was shown to be effective in 
reducing breast cancer mortality in women ages 50-74, and breast cancer survival rates drop 
significantly when cancer is detected in later stages.143  In 2016, the US Preventive Services 
Task Force (USPSTF) recommended biennial screening among women ages 50-74.20 Despite 
these potential benefits and the high level recommendation for screening, socioeconomic 
disparities continue to exist in screening utilization, which can have tremendous impact on the 
population-level benefits of these early detection practices.37  
 Unemployment could serve as a contributor to lower screening utilization and 
persistence of disparities in screening mammography use among women.  Recent studies have 
shown that unemployment is associated with decreased cancer screening utilization.144–148  The 
findings have indicated that job insecurity or unstable job positions can lead to greater stress 
and pressure that could influence an individual’s time or willingness to undergo cancer 
screening.149 Furthermore, unemployment or job insecurity can lead to a loss of employer-
sponsored health insurance, which could affect an individual’s ability to afford health insurance 
and access to a usual source of care, both of which are factors shown to lower screening 
mammography utilization.150–154 Given these findings, it is possible that times of economic 
downturn, which are felt at a population level, could expand the current screening disparities.   
 Between 2007 and 2009, the US experienced the Great Recession, a time period of 
major spikes in unemployment, and lower healthcare utilization due to an acute decrease in 
employer-sponsored insurance.155 While one recent study found higher rates of unemployment 
during the recession associated with decreased breast cancer incidence and treatment, it is 
unclear if the lower cancer incidence is related to decreases in screening mammography 
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utilization.156  Furthermore, it is unclear if certain groups of women already facing screening 
disparities were further disproportionately affected by these recession effects.   
 The objective of this study was to examine the effect of employment status on screening 
mammography utilization within a nationally representative cohort of women before, during and 
after the Great Recession (2007-2009).  We also aim to assess temporal trends and potential 
differences by race/ethnicity in this effect. Our primary hypothesis was that being less than full-
time employed during the Great Recession would lead to decreased screening mammography 
utilization.   
4.3 METHODS 
Study Design and Sample 
 We used data from the Health and Retirement Study (HRS), a national, observational, 
longitudinal panel study started in 1992 that surveys a representative sample of 
noninstitutionalized Americans ages 50 and older and their spouses every two years.157  To 
maintain a “steady state” sample, a new cohort of individuals ages 50-55 years were added 
every 6 years.158,159 This study utilizes data measured in 2002, 2004, 2006, 2008, 2010 and 
2012 HRS waves.  We included women ages 50-64 years, excluding women over age 64 who 
have an annual mammogram covered under Medicare Part B insurance.  We also excluded any 
women with a prior cancer diagnosis to remove any women with prior breast cancer.  To avoid 
extreme standard errors in our analyses, we also excluded women in 15 US states or territories 
where the number of included women in any study wave was less than 11.  Our final analytic 
sample included 8,512 women. 
Outcome 
 The primary outcome was self-reported mammogram utilization since the previous wave.   
Questions regarding mammogram uptake were asked of the entire sample of women every four 
years, so mammogram utilization data was extracted from years 2004, 2008 and 2012.  
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Specifically, women were asked if they received a mammogram or x-ray of the breast to search 
for cancer since the previous interview (two-year reporting window), 
Predictor and Covariates 
 The main predictor of interest was a woman’s employment status—measured as current 
status in the labor force during the years 2002, 2006 and 2010.  These data were purposively 
lagged; employment status was extracted from HRS waves prior to the 2-year outcome 
reporting windows to ensure temporality between the predictor and screening mammography 
utilization.  Employment status was classified as working full-time, part-time (includes individuals 
reporting being partially retired), unemployed, retired, or other (includes disabled and individuals 
not in the labor force).  This variable was created using responses from multiple HRS 
employment variables.160  Full-time status was defined as working ≥35 hours per week for ≥36 
weeks per year, whereas less than this was considered part-time.   Women defined as 
unemployed were not currently working for pay, but still looking for work.  Retirement status was 
defined as any mention of retirement in other employment questions and the woman was not 
looking for a job.  If a woman mentioned retirement but was still working, she was considered 
“partially retired”, and grouped with women who were working part-time.  All other employment 
statuses, being disabled or not in the work force, were grouped into the “other” category, 
creating five employment categories overall.  We also included insurance status as a second 
predictor, which was self-reported insurance at the time of interview and tested potential effect 
modification of this relationship by employment status.  This was measured in years 2002, 2006 
and 2010.   
 Covariates included age, race/ethnicity, education, marital status, poverty status based 
on household income and state-level yearly unemployment measures.  Race/ethnicity was 
categorized first by Hispanic ethnicity, and then separated into whether individuals were White, 
Black or other.  Aggregate state-level measures of yearly unemployment were ascertained from 
the US Department of Labor.161 Poverty status and aggregate state-level measures of yearly 
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unemployment were treated as time-varying covariates and were ascertained from the years 
2002, 2006 and 2010.  
Statistical Analysis 
 Data were weighted to better reflect US population-level estimates using HRS-provided 
weights.157,158 Individual respondent weights were standardized around a mean of 1 within each 
year. We measured differences in covariates over time using Cochran-Armitage trend test with 
a two-sided p-value of 0.05 used to determine statistical significance.  We also compared 
covariates by employment status group using chi-square tests with a two-sided p-value of 0.05 
used to determine significance.   
We used mixed-effects logistic regression models to assess the effect of employment 
status (reference group is full-time employment) on screening mammography utilization. A 
second analysis was conducted to test the effect of insurance status on screening 
mammography utilization.  We included state-level random effects to account for correlation 
among women based on state-level policies around preventive care, particularly cancer 
screening.  Models were adjusted for age, race/ethnicity, education, marital status and state-
level unemployment rate.  Poverty status was also included as a covariate in the second 
analysis examining insurance status as the main predictor.  We included interaction terms for 
the exposure and year to assess whether the effect of employment status or insurance status 
on screening mammography utilization varied across time.  We were interested in three time 
periods: prior to the Recession (2002-2004), during the Recession (2006-2008) and after the 
Recession (2010-2012).  We also tested for potential interaction by race/ethnicity.   
For the second analysis, we also included interaction terms for insurance status and 
employment status, to assess whether the effect varied by employment status.  A two-sided p-
value of 0.10 was used to determine statistical significance of interaction.  Regression 
coefficients were exponentiated to calculate odds ratios and corresponding 95% confidence 
intervals (CI) and converted to probabilities to calculate predicted probabilities of screening 
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mammography use for each employment status across time. Statistical analyses were 
performed using SAS 9.4 (SAS Corporation, Cary, NC).   
4.4 RESULTS 
Our study included 8,512 US women ages 50-64 across 35 states.  Table 4.1 presents 
the descriptive information for all women in the analytic sample.  Most participants in our sample 
were ages 55 and older (77%), non-Hispanic White (76%), married (68%) and had at least 
some college education (55%).  Table 4.2 presents proportions of time-varying covariates by 
year.  The percentage of uninsured women significantly increases from 2002 (20%), to 2006 
(23%), to 2010 (27%) with a p-trend of <0.01.   The proportions of full-time employed (2002: 
38% to 2010: 45%) and unemployed women (2002: 3% to 2010: 5%) increased over time, while 
the proportion of women with “other” employment status decreased over time (2002: 20% to 
2010: 12%), each with p-trend values of <0.01. 
 When stratifying covariates by employment status, all covariates were found to be 
significantly different by employment status group with chi-square p-values of <0.01 (Table 4.3).  
Women who had full-time employment were ages 55 and older (72%), mostly non-Hispanic 
White (79%), mostly had at least some college education (63%), were married or partnered 
(65%) and were mostly insured (89%).  Unemployed women, which made up only 3% of the 
study population, were mostly ages 55 and older (72%), had at least some college education 
(52%), and only 54% were insured, the lowest rate among all employment groups. Part-time 
employed women had at least some college education (59%) and were mostly married (75%).  
Retired women were mostly ages 60 and older (58%) and mostly had a high school diploma or 
less (54%). Women designated as having an “other” employment status (on disability or not in 
the labor force) had a high school diploma or less (66%), were mostly married or partnered 
(74%), included 24% of women below the poverty line, and only 56% were insured.   
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 Overall, rates of screening mammography were 77% in 2004, 76% in 2008 and 69% in 
2012. Women with full-time employment had a 76% predicted probability (95% CI: 73%, 78%) of 
screening mammography utilization, which was comparable to retired women (Probability: 73%, 
95% CI: 70%, 77%) (Table 4.4).  Unemployed (70%, 95% CI: 64%, 75%), part-time employed 
(71%, 95% CI: 68%, 75%) and women with other employment (71%, 95% CI: 67%, 75%) had 5-
6% lower probability of screening mammography utilization.  Overall, women who had part-time 
employment (OR: 0.80, 95% CI: 0.70, 0.92), were unemployed (OR: 0.76, 95% CI: 0.60, 0.97), 
or were classified as having an “other” type of employment status (disability or not in work force) 
(OR: 0.79, 95% CI: 0.68, 0.91) had decreased odds of screening mammography utilization 
compared to women with full-time employment.  In summary, part-time employed, women with 
“other” employment and unemployed women had the lowest rates of screening mammography. 
In addition to the overall findings that less than full-time employment status was 
associated with increased screening mammography utilization, we found no significant 
interaction between employment status and study wave (p=0.50) (Table 4.4).    Among women 
who had part-time employment, odds of screening increased from 2002-2004 (OR: 0.73, 95% 
CI: 0.55, 0.96) to 2006-2008 (OR: 0.91, 95% CI: 0.71, 1.16) then decreased in 2010-2012 (OR: 
0.78, 95% CI: 0.65, 0.95).  Among women with other employment, screening mammography 
odds decreased from 2002-2004 (OR: 0.82, 95% CI: 0.63, 1.07) to 2006-2008 (OR: 0.66, 95% 
CI: 0.51, 0.85) and then increased in 2010-2012 (OR: 0.88, 95% CI: 0.70, 1.10).  There was 
also no interaction between employment status and race/ethnicity (p=0.27). 
Additionally, when assessing the effect of insurance status on screening utilization, lack 
of insurance (OR: 0.46, 95% CI: 0.39, 0.53) was associated with significantly decreased 
screening mammography utilization (Table 4.5).  There was also significant interaction between 
employment status and insurance status (p<0.01).   Across all employment status groups, there 
was a significant difference in predicted probability of screening mammography use when 
comparing women with versus without insurance.  Part-time employed women who were 
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uninsured (OR: 0.32, 95% CI: 0.24, 0.41) had the lowest odds of screening compared to insured 
women.  Women with “other” employment who were uninsured (OR: 0.71, 95% CI: 0.54, 0.91) 
only had a 29% decreased odds of screening mammography compared to insured women who 
had “other” employment.    
4.5 DISCUSSION 
 In a nationally representative study of women ages 50-64, our findings showed that 
employment status was significantly associated with odds of screening mammography 
utilization. Treating full-time employment as a reference, women who had part-time 
employment, were unemployed, or had “other” employment status defined by disability or not 
being in the labor force had decreased odds of screening mammography utilization, aligning 
with our hypothesis that employment status directly affects someone’s likelihood to screen. 
However, our findings indicate that the associations between employment status and screening 
mammography did not vary meaningfully across the three studied time periods (2002-2004, 
2006-2008, 2010-2012).   Further, in a secondary analysis of the effect of insurance status on 
screening mammography utilization, lack of insurance significantly decreased screening 
mammography odds, and the effect varied by employment status. 
 Our findings were similar to prior studies that have evaluated how employment status 
affected screening utilization.162,163  In a cross-sectional study, Calo et al. found that census 
tract-level unemployment was associated with decreased colorectal cancer screening 
adherence, potentially representing a breakdown in healthcare access within an area of high 
unemployment or economic instability.162 Hamad et al. similarly found that outpatient healthcare 
utilization overall decreased among individuals at manufacturing plants where there were higher 
rates of layoffs in a cohort study.163 Our study found significant effects among employment 
status groups indicating less than full-time employment, with the exception of being retired.       
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Prior studies measuring trends in cancer screening before, during and after the Great 
Recession, did not consider the independent effect of employment status on screening 
utilization.  Wyatt et al. found that screening mammography odds decreased during the Great 
Recession, and then decreased again during the post-Recession, Affordable Care Act initiation 
period, when measuring trends over time.164 While our findings show a downward trend in the 
predicted probability of screening mammography utilization across most employment status 
groups, the magnitude of the effect of employment status on screening mammography did not 
meaningfully change across time.   
The results indicating similar screening mammography utilization probabilities among 
retired women compared to full-time employed women both overall and over the course of the 
Great Recession aligned with findings from previous studies.145,164  Both Fedewa et al. and 
Wyatt et al. included adults ages 50 and older in their study whereas our study only included 
women ages 50-64, which would likely only include women who have retired early, who might 
be different from persons who do not retire early.145,164  While US citizens earn the full benefits 
of retirement around age 65 or older, citizens may retire at age 62 and start receiving Social 
Security benefits with percentage reductions based on the number of months prior to the 
defined “full retirement age”.165 Despite this early access to Social Security, retirees do not gain 
earlier access to Medicare, which covers preventive screenings such as mammography.166 
Thus, it is possible that this sustained access to screening is related to potential unmeasured 
factors related to being retired. 
Insurance status was also found to have an independent effect on screening 
mammography utilization, with uninsured women having markedly lower likelihood of 
undergoing mammography compared to their insured counterparts.  This effect was stable over 
time and persisted across all employment groups.  These findings align with prior research, 
which indicated that insurance access is positively associated with greater screening 
mammography utilization.164,167  Rates of insurance status decreased over the course of the 
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Great Recession, highlighting a critical need to better understand the importance of insurance 
status on cancer screening uptake, particularly in times of economic downturn.   
The findings of lower screening mammography utilization overall among part-time, 
unemployed or other employment type women could be related to less time and resources, 
which has previously been considered a barrier to receiving preventive care.148 Kim et al. 
evaluated the effect of job status on accessibility to cancer screening among wage earners, 
finding that part-time workers had difficulty participating in prevention programs.168 This aligns 
with research in behavioral economics around the theory of “effect budgeting”, where people 
have limited time that requires prioritization of all tasks and activities.169 Catalano et al. suggest 
that given these limited resources, we budget them in a way to reflect expected costs and 
benefits, particularly in times of economic downturn, when priorities and resources can 
change.169 This would align with the findings of decreases in screening mammography 
utilization across all employment status groups after the Great Recession (2010-2012 analysis).  
Our study findings indicate that women with less than full-time employment have lower odds of 
screening utilization, but the Great Recession did not exacerbate this effect.   
Our study had some limitations.  Mammography use was only measured every four 
years, limiting more consistent measure of routine screening mammography, which is 
recommended biennially.  Furthermore, mammography use was measured via self-report, which 
has previously been found to potentially lead to overestimation of the true mammography 
utilization.170  We did not follow women to potential breast cancer outcomes to measure if 
mammography use differences by employment status affected breast cancer risk.  Future 
studies could extend these findings to better understand if such an association exists.   
Despite these limitations, our study had key strengths including leveraging a national, 
diverse population-based cohort of women to measure longitudinal uptake of screening 
mammography over a 10-year period.  This differs from prior studies, which have considered 
cross-sectional study waves without longitudinal follow-up of individuals.163,164 In addition, the 
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analyses were weighted to reflect a population-based sample, improving generalizability of the 
sample.  The use of mixed modeling also enabled clustering of state-level Great Recession 
effects to better estimate local economic impacts.  To ensure the robustness of our models, we 
tested both a lagged longitudinal model as well as three time-stratified models reflecting effects 
before, during and after the Great Recession, finding similar results among the different model 
types.  We also tested a positive control effect, measuring the independent effect of 
employment status on insurance status.  The findings confirmed that our tested covariates were 
appropriate, and further confirmed that while an effect of employment status on insurance status 
differed over time, a similar effect did not exist for our tested research question.  
4.6 CONCLUSION 
Overall, part-time employed women, unemployed women and women who were 
disabled or out of the work force (“other” employment status) were less likely to get a screening 
mammogram compared to full-time employed women.  Furthermore, our findings indicated that 
the association between employment status and screening mammography did not significantly 
vary over the course of the Great Recession, though probability of screening mammography 
utilization decreased across all employment status groups over the course of the study.  Similar 
to other studies, uninsured women had lower predicted probability of screening and lower odds 
of screening mammography utilization in all employment status groups compared to insured 
women, particularly among full-time employed and part-time employed women.  These findings 
highlight an important need to learn about how employment status affects cancer screening 
utilization in women, and how insurance access factors into this relationship in light of recent 
health care reform and changes to health care access. 
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Table 4.1: Overall proportions of covariates across study population 
  Overall Weighted % 
Age (%)   
50-54 23 
55-59 43 
60-64 34 
Race/Ethnicity (%)   
Non-Hispanic White 76 
Non-Hispanic Black 12 
Hispanic 9 
Other 4 
Education (%)   
Less than High School 12 
High School Diploma or GED 33 
Some College 28 
College Graduate or Higher 27 
Marital Status (%)   
Married or Partnered 68 
Separated/Divorced/Widowed 27 
Not Married 5 
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Table 4.2: Overall proportions of selected covariates across study waves 
 
Baseline  
(2002-2004) 
% 
During 
(2006-2008) 
% 
After 
 (2010-2012) 
% 
P-Value 
Poverty Status (%)       0.16 Below Poverty Line 11 9 11 
Insurance Type (%)        
Insured 80 77 73 <0.01 
Private 68 67 65 <0.01 
Public 5 4 3 <0.01 
Other 8 6 6 <0.01 
Uninsured 20 23 27 <0.01 
Employment Status (%)        
Full-time Employment 38 44 45 <0.01 
Part-time Employment or 
Partial Retirement 18 18 19 0.31 
Unemployed 3 2 5 <0.01 
Retired 21 21 19 <0.01 
Other 20 15 12 <0.01 
Percentages are based on weighted sample using HRS weights 
Two-sided P-values correspond to Cochran-Armitage trend tests
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5. CONCLUSIONS 
The three studies described within this dissertation critically assessed the effects of 
multilevel factors across the socioecological environment of cancer early detection for screening 
uptake, clinical practices and methodology, and social determinants on utilization.  The first 
study found that greater comorbidity, functional limitations, and lower perceived health were 
associated with lower mammography utilization, indicating that providers should weigh these life 
expectancy factors when making screening mammography recommendations for their elderly 
patients.  In the second study, wide variation in radiation dose for lung cancer screening scans 
was documented, and institutions limiting protocol creation to lead radiologists and hiring 
internal medical physicists had lower radiation doses.  In the third study, the Great Recession 
decreased odds of screening mammography utilization across part-time employed women, 
unemployed women and “other” employed women (disabled women or women out of the labor 
force).  However, the most pronounced effect was among uninsured women, who had a 
significantly lower likelihood of screening mammography utilization compared to insured 
women, independent of employment status.  Overall, the findings from each socioecological 
level provide a lens on different but interacting contexts and solutions to key issues that exist in 
the cancer screening environment.   
 Numerous cancer screening studies in recent years have considered multilevel factors 
in their research questions to better understand predictors of cancer screening uptake.  Shariff-
Marco et al. measured the effect of individual-level and neighborhood-level predictors on 
colorectal cancer screening uptake, concluding that factors such as locality, primary care 
resources and membership in a health maintenance organization (HMO) were key determinants 
of colorectal cancer screening uptake, while socioeconomic status and segregation did not 
predict uptake.171 A study conducted by Hubbard et al. using data from the Breast Cancer 
Surveillance Consortium linked with Medicare claims data assessed individual-level and 
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community-level predictors of long-term adherence to screening mammography among older 
women, finding that women with less than a high school education and a Charlson Comorbidity 
Index score of at least one were more likely to be non-adherent at baseline and less likely to 
remain adherent over time.77 The findings were critical to identifying vulnerable populations who 
may not be screening or adhere to screening guidelines, which can pave the way for more 
targeted interventions to optimize screening uptake. 
The first chapter of this dissertation contributed a comprehensive review of the current 
evidence around how life expectancy factors affect screening mammography utilization, making 
a crucial argument for more targeted guidelines for screening among older women.  As 
described previously, a primary determinant of screening mammography uptake is a physician’s 
recommendation.111–113 Without properly accounting for life expectancy when a physician 
recommends whether a woman should under screening mammography, it is possible that a 
benefit be limited, potentially opening an older woman up to greater risk of experiencing 
deleterious effects.  Schonberg et al. are testing a screening mammography decision aid to 
inform women ages 75 and older of the potential harms of undergoing further screening, 
particularly among those with limited life expectancy.110 While the goal of this decision aid is to 
strengthen the autonomy of older women unsure of whether to screen, future decision aid 
research should also incorporate the provider in this discussion to maintain healthy patient-
provider communication that could be critical to other aspects of women’s health.  
As evidenced from the second study, identifying key institutional-level predictors can 
help target areas of concern that can be optimized to improve the quality of cancer screening to 
maximize the margin of benefit.  In another study also looking at lung cancer screening, Carter-
Harris and Gould identified key patient-level, provider-level and system-level barriers to 
implementation of an effective lung cancer screening program, advocating that effective 
screening implementation should consider all of these factors to proactively address potential 
challenges that might arise.172 Additionally Kim et al. measured patient-level and provider-level 
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factors affecting colorectal cancer screening uptake, and found that having an annual physical 
exam, being non-Hispanic White, and having a provider with medical doctor credentials were 
the strongest predictors of increased screening uptake.173 Focusing on system-level and 
provider-level factors illustrates the critical role the provider plays in both encouraging 
appropriate screening uptake and ensuring screening tests are performed to the highest 
standard.    
The findings from the third study indicated that employment status affects screening 
mammography utilization, and insurance status also affects screening mammography utilization, 
though neither effect was exacerbated by the Great Recession.  Prior research shows that 
individuals are not likely to change their screening behavior unless strongly compelled to do 
so.174 Thus, the persistence of disparities in cancer screening tends to be related to the factors 
influencing the individual’s initial intent or capacity to screen.174  Better understanding these 
factors can help uncover an underlying context that affects the likelihood that an individual will 
use screening services.  Furthermore, these findings could further help clinicians develop more 
targeted interventions or make screening more appropriately accessible for the individuals with 
the greatest need.   
In sum, the findings from this dissertation illustrate three different scenarios across a 
multilevel cancer screening framework in which research can help fill current evidence gaps.  
Within the cancer screening environment, many interdependent factors influence whether 
individuals undergo screening, how screening is implemented, and the current guidelines for 
insurance coverage of screening.  Future studies into predictors of cancer screening uptake and 
performance should examine factors at multiple socioecological levels more comprehensively in 
order to understand how different predictors are influenced by the complex cancer screening 
environment.  Identifying the role these factors play can improve upon current interventions to 
optimize cancer screening uptake and ensure that screening tests maximize potential benefits 
while minimizing potential harms.    
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